Lobular panniculitis and diffuse osteonecrosis occurring during anti-MEK and anti-BRAF combination therapy for metastatic melanoma

S Tzoumpa¹, B Villette¹, A C Tieng¹, C Bejar¹, L Rousset¹, V Heidelberger¹, M Playe², C Desbene³, B Khalifa⁴, C N'Guessan-Koffi⁵, T Braun^{6

7}, S Le Jeune^{7

8}, F Caux^{1

7}, E Maubec^{1

7

9}

Affiliations

¹ Department of Dermatology, Avicenne University Hospital, AP-HP, Bobigny, France.
² Department of Nuclear Medicine, Avicenne University Hospital, AP-HP, Bobigny, France.
³ Biochemistry Laboratory, Avicenne University Hospital, AP-HP, Bobigny, France.
⁴ Department of Pathology, Avicenne University Hospital, AP-HP, Bobigny, France.
⁵ Agence Générale des Équipements et Produits de Santé (AGEPS), AP-HP, Paris, France.
⁶ Department of Hematology, Avicenne University Hospital, AP-HP, Bobigny, France.
⁷ Sorbonne Paris Nord University - Campus de Bobigny, Bobigny, France.
⁸ Department of Internal Medicine, Avicenne University Hospital, AP-HP, Bobigny, France.
⁹ UMRS-11 24, Campus Paris Saint-Germain-des-Prés, Paris University, Paris, France.

S Tzoumpa et al. J Eur Acad Dermatol Venereol. 2023.

. 2023 Mar 28.

doi: 10.1111/jdv.19077. Online ahead of print.

¹ Department of Dermatology, Avicenne University Hospital, AP-HP, Bobigny, France.
² Department of Nuclear Medicine, Avicenne University Hospital, AP-HP, Bobigny, France.
³ Biochemistry Laboratory, Avicenne University Hospital, AP-HP, Bobigny, France.
⁴ Department of Pathology, Avicenne University Hospital, AP-HP, Bobigny, France.
⁵ Agence Générale des Équipements et Produits de Santé (AGEPS), AP-HP, Paris, France.
⁶ Department of Hematology, Avicenne University Hospital, AP-HP, Bobigny, France.
⁷ Sorbonne Paris Nord University - Campus de Bobigny, Bobigny, France.
⁸ Department of Internal Medicine, Avicenne University Hospital, AP-HP, Bobigny, France.
⁹ UMRS-11 24, Campus Paris Saint-Germain-des-Prés, Paris University, Paris, France.

No abstract available

References

1. Ascierto P, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J Clin Oncol. 2023;41:212-21.
1. Galliker NA, Murer C, Kamarashev J, Dummer R, Goldinger SM. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of BRAF inhibitor and MEK inhibitor. Eur J Dermatol. 2015;25:177-80.
1. Piroth M, Frénard C, Eugène-Lamer J, Dreno B, Quéreux G. Panniculitis during BRAF inhibitor and/or MEK inhibitor therapy: a new case report and literature review. Ann Dermatol Venereol. 2020;147:833-41. (in French).
1. Bartlett DJ, Erie AJ, Baffour FI, Broski SM, Glazebrook KN. BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series. Skeletal Radiol. 2021;50:1257-62.
1. Duperrat B, Gaquiere A, Bismuth V. Weber-Christian disease with multiple localisations: cutaneous, mesenteric and osseous. Bull Mem Soc Med Hop Paris. 1963;114:1235-40. (article in French).